A Phase 1/2 interventional study of Required Field in Ischemic Stroke, sponsored by Taipei Hospital, Ministry of Health and Welfare. Enrolling by invitation at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-08-25.
Sponsored by Taipei Hospital, Ministry of Health and Welfare · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Ischemic Stroke with a site in Taiwan — 18 open to participants now, 21 under way, 3 of them phase 3. Ischemic Stroke · Taiwan.
Among the 64 studies in Ischemic Stroke with a site in Taiwan, this one is the 47th largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 11 of the 20 other live ones, and was the 62nd registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →18 of the 64 studies in Ischemic Stroke with a site in Taiwan are open now. Recruiting first, the newest first:
Lumosa Therapeutics Co., Ltd. · Sites in Taiwan
Ages 18–88
En Chu Kong Hospital · Sites in Taiwan
Ages 20+
Boehringer Ingelheim · Sites in Taiwan, Argentina, Australia and 13 more countries
Ages 18+
Taichung Veterans General Hospital · Sites in Taiwan
Ages 18–90
Chang Gung Memorial Hospital · Sites in Taiwan
Ages 20–100
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 10 · Phase 4 1
First in 2005; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 9 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 73 across the 52 interventional studies, 200 across the 12 observational. Of the 30 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 64 have an industry lead sponsor. The 10 most frequent:
Taipei Hospital, Ministry of Health and Welfare is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Taipei Hospital, Ministry of Health and Welfare has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
4 of the studies in Ischemic Stroke with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07361302Phase 3Boehringer IngelheimA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | 2027-10-02 |
| NCT05198323Lumosa Therapeutics Co., Ltd.A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT | 2026-12-31 |
| NCT07784751Taipei Hospital, Ministry of Health and WelfareSafety, Dose-Finding, and Efficacy of Transcranial Pulse Stimulation for Post-Stroke Neurorehabilitation | 2027-08-24 |
| NCT07900503En Chu Kong HospitalSafety and Feasibility of NRICM301 Added to Usual Care for Adults With Acute Ischemic Stroke | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 64 studies in Ischemic Stroke with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the safety, tolerability, dose-response, and preliminary efficacy of transcranial pulse stimulation (TPS) for neurorehabilitation in patients with ischemic stroke. Participants will receive TPS at different energy levels in a dose-escalation design. Clinical and neurophysiological assessments will be conducted to evaluate changes in motor function, balance, quality of life, and brain activity.
This is a prospective, interventional, non-randomized, open-label dose-finding study evaluating the safety, tolerability, and preliminary efficacy of transcranial pulse stimulation (TPS) in patients with ischemic stroke.
Participants will receive TPS using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). The study will use a sequential dose-escalation design with three energy levels: 0.15, 0.20, and 0.25 mJ/mm². Each participant will receive TPS three times per week for 2 weeks, for a total of 6 treatment sessions. Each session will deliver 4,000 pulses at a frequency of 4 Hz.
The primary focus of the study is to evaluate the safety and tolerability of different TPS energy levels. Secondary and exploratory assessments will evaluate changes in motor function, balance, activities of daily living, quality of life, and neurophysiological measures. Electroencephalography (EEG) and functional near-infrared spectroscopy (fNIRS) will be used to assess changes in brain activity associated with treatment.
The study plans to enroll 9 participants initially, with 3 participants assigned to each dose level. Dose escalation will proceed after safety evaluation of the preceding dose level. If the predefined safety criteria are met, the study may be expanded to include additional participants.
Participants will receive transcranial pulse stimulation (TPS) at an energy level of 0.15 mJ/mm², three times per week for 2 weeks, for a total of 6 treatment sessions. Participants will receive transcranial pulse stimulation (TPS) at an energy level of 0.20 mJ/mm², three times per week for 2 weeks, for a total of 6 treatment sessions. Participants will receive transcranial pulse stimulation (TPS) at an energy level of 0.25 mJ/mm², three times per week for 2 weeks, for a total of 6 treatment sessions.
Device: Required Field
Participants will receive transcranial pulse stimulation (TPS) using the NEUROLITH® TPS system (Storz Medical AG, Switzerland). TPS will be administered at the assigned energy level of 0.15, 0.20, or 0.25 mJ/mm², at a frequency of 4 Hz, with 4,000 pulses per session. Treatment will be administered three times per week for 2 weeks, for a total of 6 treatment sessions. Dose escalation will proceed sequentially after safety evaluation of the preceding dose level.
Incidence of Dose-Limiting Toxicity (DLT) and Adverse Events
Safety monitoring including adverse events (AEs), serious adverse events (SAEs), and DLT defined as: NIHSS increase ≥4 points lasting ≥24-48 hours, new-onset seizure, new or worsening neurological deficits, intolerable persistent AEs (headache, dizziness, nausea), or acute MRI worsening (new DWI stroke, hemorrhage, or severe edema).
Time frame: Baseline, 2 weeks (immediately post-treatment), and 1 month post-treatment
Plan to share: Yes — Individual participant data will not be publicly shared to protect participant privacy and maintain confidentiality in accordance with institutional review board (IRB) guidelines and local data protection regulations.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Start Date: August 24, 2026. End Date: August 24, 2027 . For one year.
Access criteria: Inclusion Criteria Age 20-80 years. Confirmed ischemic stroke, supported by imaging (MRI). Stroke time between: subacute phase: more than 1 month to within 6 months of onset. NIHSS score 4-25, with objectively assessable motor or speech deficits. (Assessment at the time of consent signing) Acute phase medical treatment completed, vital signs stable.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Aug 2027, 12 months after the start.
Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Hospital, Ministry of Health and Welfare